Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.50 |
| ▸ | AHR | P35869 | 5/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435859 | 1.00 | RHEB (0.50) | RHEBAHRCSNK2A1ALDH1A1CMA1 | |
| SCHEMBL1020056 | 0.78 | AHR (0.54) | RHEBAHRCSNK2A1ALDH1A1NR4A2 | |
| SCHEMBL1022450 | 0.78 | RHEB (0.58) | RHEBAHRCSNK2A1ALDH1A1CMA1 | |
| SCHEMBL29644241 | 0.78 | AHR (0.54) | RHEBAHRCSNK2A1ALDH1A1NR4A2 | |
| SCHEMBL29531208 | 0.78 | RHEB (0.58) | RHEBAHRCSNK2A1ALDH1A1CMA1 | |
| SCHEMBL25254260 | 0.75 | RHEB (0.50) | RHEBAHRCSNK2A1ALDH1A1CMA1 | |
| SCHEMBL827753 | 0.75 | RHEB (0.50) | RHEBAHRCSNK2A1ALDH1A1CMA1 | |
| SCHEMBL996179 | 0.75 | AHR (0.50) | RHEBAHRCSNK2A1ALDH1A1NR4A2 | |
| SCHEMBL1431448 | 0.75 | RHEB (0.50) | RHEBAHRCSNK2A1ALDH1A1NR4A2 | |
| SCHEMBL1020747 | 0.75 | RHEB (0.50) | RHEBAHRCSNK2A1ALDH1A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2026-03-17 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250289805-A1 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12338231-B1 | N-heterocycle substituted tryptamine derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2025-06-24 | — | — | US | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2012163456-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012163792-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302597-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8232290-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| CN-102046240-A | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG | 2011-05-04 | — | — | CN | disclosed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | RHEB 1460/4885AHR 4300/4885CSNK2A1 404/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | RHEB 4554/4885AHR 82/4885CSNK2A1 2/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | RHEB 377/4885AHR 3391/4885CSNK2A1 909/4885 |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | RHEB 1207/4885AHR 685/4885CSNK2A1 318/4885 |
| US-20250289805-A1 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR2C, HTR2A, HTR5A | RHEB 3375/4885AHR 178/4885CSNK2A1 2418/4885 |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | HTR2C, TPH2, HTR4 | RHEB 2105/4885AHR 136/4885CSNK2A1 1056/4885 |
| US-20120302597-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | RHEB 4753/4885AHR 328/4885CSNK2A1 2599/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | RHEB 377/4885AHR 3391/4885CSNK2A1 909/4885 |
| US-12338231-B1 | N-heterocycle substituted tryptamine derivatives and methods of using | HTR2C, HTR2A, HTR5A | RHEB 3375/4885AHR 178/4885CSNK2A1 2418/4885 |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | RHEB 4753/4885AHR 328/4885CSNK2A1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.